Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study

Medicine & Life Sciences

• Fenofibrate 100%
• Coronary Artery Disease 60%
• Atherosclerosis 59%
• Lipoproteins 55%
• Type 2 Diabetes Mellitus 55%
• Placebos 40%
• Pathologic Constriction 23%
• low density lipoprotein triglyceride 17%
• Intention to Treat Analysis 17%
• Diabetes Complications 14%
• Hyperglycemia 13%
• LDL Cholesterol 13%
• HDL Cholesterol 13%
• Coronary Disease 13%
• Hemoglobins 11%
• Angiography 11%
• Cholesterol 10%
• Lipids 9%
• Therapeutics 4%